SCHEMBL137900

SCHEMBL137900

c1cncc(C2COCCN2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 9/20 0.59
CHRNA4 P43681 9/20 0.59
CHRNA7 P36544 7/20 0.58
CYP2A6 P11509 4/20 0.57
MEN1 O00255 2/20 0.57
CYP2D6 P10635 2/20 0.57
CYP2C19 P33261 2/20 0.57
KMT2A Q03164 2/20 0.57
POLB P06746 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
PRKACA P17612 1/20 0.44
PRKACG P22612 1/20 0.44
PRKACB P22694 1/20 0.44
CYP11B2 P19099 1/20 0.42
ALDH1A1 P00352 2/20 0.40
CHRNB4 P30926 2/20 0.40
CHRNA3 P32297 2/20 0.40
CHRNA2 Q15822 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30240863 1.00 CHRNB2 (0.59) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
Hydrochloric Acid SCHEMBL31227410 0.98 CHRNB2 (0.57) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
SCHEMBL19142439 0.81 PRKACA (0.41) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
SCHEMBL1333525 0.80 PRKACA (0.49) MEN1KMT2APRKACAPRKACGPRKACB
SCHEMBL1333528 0.80 PRKACA (0.49) MEN1KMT2APRKACAPRKACGPRKACB
SCHEMBL1335278 0.80 PRKACA (0.49) MEN1KMT2APRKACAPRKACGPRKACB
Hydrochloric Acid SCHEMBL1849039 0.79 PRKACA (0.48) MEN1KMT2APRKACAPRKACGPRKACB
SCHEMBL20038413 0.75 ACVR1 (0.41) CHRNB2CHRNA4CHRNA7PRKACAPRKACG
SCHEMBL15949239 0.75 CSNK1D (0.38) CHRNB2CHRNA4CHRNA7CYP2A6MEN1
SCHEMBL18291309 0.75 ACVR1 (0.41) CHRNB2CHRNA4CHRNA7PRKACAPRKACG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 US disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 EP disclosed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
WO-2024133200-A1 P2X3 RECEPTOR ANTAGONISTS RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) 2024-06-27 WO disclosed
EP-4389746-A2 P2X3 RECEPTOR ANTAGONISTS Recordati Industria Chimica E Farmaceutica SPA (IT) 2024-06-26 EP disclosed
US-11999732-B2 P2X3 receptor antagonists RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) 2024-06-04 US disclosed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-112041319-B Triazole, imidazole and pyrrole fused piperazine derivatives and their use as mGlu5Use of modulators of receptors 利康化学与制药工业有限公司 2024-05-14 CN disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
CN-112584898-B P2X 3 Receptor antagonists 瑞蔻达蒂化学和制药工业股份有限公司 2024-01-26 CN disclosed
EP-1951842-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS BASF SE (DE) 2008-08-06 EP disclosed
CN-101223172-A Substituted rylene derivatives BASF SE (DE) 2008-07-16 CN disclosed
US-20080167467-A1 Substituted Rylene Derivatives BASF AKTIENGESELLSCHAFT (DE) 2008-07-10 US disclosed
EP-1904497-A1 SUBSTITUTED RYLENE DERIVATIVES BASF SE (DE) 2008-04-02 EP disclosed
CN-101068790-A Rylene tetracarboxylic acid diimides substituted by cyclic amino groups BASF AG (DE) 2007-11-07 CN disclosed
WO-2007099059-A1 USE OF RYLENES AS MARKERS FOR LIQUIDS BASF SE (DE) 2007-09-07 WO disclosed
EP-1819678-A1 RYLENE TETRACARBOXYLIC ACID DIIMIDES SUBSTITUTED BY CYCLIC AMINO GROUPS BASF AKTIENGESELLSCHAFT (DE) 2007-08-22 EP disclosed
WO-2007054470-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS BASF SE (DE) 2007-05-18 WO disclosed
WO-2007006717-A1 SUBSTITUTED RYLENE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2007-01-18 WO disclosed
WO-2006058674-A1 RYLENE TETRACARBOXYLIC ACID DIIMIDES SUBSTITUTED BY CYCLIC AMINO GROUPS BASF AKTIENGESELLSCHAFT (DE) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167467-A1 Substituted Rylene Derivatives NR3C2, NR2C2, NR2E3 CHRNB2 159/4885CHRNA4 218/4885CHRNA7 478/4885
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 CHRNB2 261/4885CHRNA4 280/4885CHRNA7 230/4885
US-11999732-B2 P2X3 receptor antagonists P2RX3, P2RX5, P2RX2 CHRNB2 358/4885CHRNA4 337/4885CHRNA7 336/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP CHRNB2 2843/4885CHRNA4 2044/4885CHRNA7 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.